Entrar/Registro  
INICIO ENGLISH
 
Gaceta Médica de México
   
MENÚ

Contenido por año, Vol. y Num.

Índice de este artículo

Información General

Instrucciones para Autores

Mensajes al Editor

Directorio






>Revistas >Gaceta Médica de México >Año 2015, No. 2


Gutiérrez-Castrellón P, Díaz-García L, de Colsa-Ranero A, Cuevas-Alpuche J, Jiménez-Escobar I
Eficacia y seguridad de la ciprofloxacina en el tratamiento de las infecciones de las vías urinarias (IVU) en adultos: revisión sistemática con metaanálisis
Gac Med Mex 2015; 151 (2)

Idioma: Español
Referencias bibliográficas: 131
Paginas: 225-244
Archivo PDF: 338.18 Kb.


Texto completo




RESUMEN

Objetivos y diseño: Revisión sistemática con metaanálisis de ensayos clínicos controlados aleatorizados (ECA) sobre la eficacia y seguridad de la ciprofloxacina en el tratamiento de las IVU agudas o complicadas en mayores de 18 años. Se consideraron como desenlaces primarios la erradicación bacteriológica, la curación clínica, las resistencias bacterianas y el porcentaje de eventos adversos. Resultados: Se identificaron 111 ECA, de los cuales se excluyeron 81 estudios. El análisis de los 30 ECA de calidad adecuada permitió identificar la equivalencia terapéutica de ciprofloxacina frente al resto de antimicrobianos para la erradicación bacteriana y la curación clínica, tanto al final del tratamiento como en etapas posteriores. El porcentaje de resistencias bacterianas fue similar en los dos grupos de contraste y el de eventos adversos relacionados fue significativamente menor en el grupo tratado con ciprofloxacina. Conclusiones: La ciprofloxacina representa una alternativa terapéutica segura y efectiva para el tratamiento de las IVU agudas o complicadas en mayores de 18 años.


Palabras clave: Ciprofloxacina, Infecciones de las vías urinarias, Adultos.


REFERENCIAS

  1. Ronald AR, Nicolle LE, Stamm E, et al. Urinary tract infection in adults: research priorities and strategies. Int J Antimicrob Agents. 2001;17(4):343-8.

  2. Bacheller CD, Bernstein JM. Urinary tract infections. Med Clin North Am. 1997;81(3):719-30.

  3. Schappert SM. National Ambulatory Medical Care Survey: 1992 summary. Adv Data. 1994;(253):1-20.

  4. Kunin CM. Urinary tract infections in females. Clin Infect Dis. 1994;18(1):1-10.

  5. Johnson JR, Stamm WE. Urinary tract infections in women: diagnosis and treatment. Ann Intern Med. 1989;111(11):906-17.

  6. Albert X, Huertas I, Pereiro II, et al. Antibiotics for preventing recurrent urinarytract infection in non-pregnant women. Cochrane Database Syst Rev. 2004;(3):CD001209.

  7. Milo G, Katchman EA, Paul M, et al. Duration of antibacterial treatment for uncomplicated urinary tract infection in women. Cochrane Database Syst Rev. 2005;(2):CD004682.

  8. Pohl A. Modes of administration of antibiotics for symptomatic severe urinary tract infections. Cochrane Database Syst Rev. 2007;(4):CD003237.

  9. Regal RE, Pham CQ, Bostwick TR. Urinary tract infections in extended care facilities: preventive management strategies. Consult Pharm. 2006;21(5):400-9.

  10. Lutters M, Vogt N. Antibiotic duration for treating uncomplicated, symptomatic lower urinary tract infections in elderly women. Cochrane Database Syst Rev. 2002;(3):CD001535.

  11. Hooton TM, Stamm WE. Management of acute uncomplicated urinary tract infection in adults. Med Clin North Ame. 1991;75(2):339-57.

  12. Hooton TM, Stamm WE. Diagnosis and treatment of uncomplicated urinary tract infection. Infect Dis Clin North Am. 1997;11(2):551-81.

  13. Neu HC. Optimal characteristics of agents to treat uncomplicated urinary tract infection. Infection. 1992;20 Suppl 4:S266-71.

  14. Naber KG. Short-term therapy of acute uncomplicated cystitis. Curr Opin Urol. 1999;9(1):57-64.

  15. Naber KG. Treatment options for acute uncomplicated cystitis in adults. J Antimicrob Chemother. 2000;46 Suppl 1:23-7.

  16. Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaeffer AJ, Stamm WE. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). Clin Infect Dis. 1999;29(4):745-58.

  17. Minassian MA, Lewis DA, Chattopadhyay D, Bovill B, Duckworth GJ, Williams JD. A comparison between single-dose fosfomycin trometamol (Monuril) and a 5-day course of trimethoprim in the treatment of uncomplicated lower urinary tract infection in women. Int J Antimicrob Agents. 1998;10(1):39-47.

  18. Sharma PC, Jain A, Jain S, Pahwa R, Yar MS. Ciprofloxacin: review on developments in synthetic,analytical, and medicinal aspects. J Enzyme Inhib Med Chem. 2010;25(4):577-89

  19. Mirone V, Fusco F, Taglialatela D, et al. Efficacy and safety of ciprofloxacin XR 1000 mg once daily versus ciprofloxacin 500 mg twice daily in the treatment of complicated urinary tract infections. J Chemother. 2009;21(6):651-60.

  20. Pfefferkorn U, Lea S, Moldenhauer J, Peterli R, von Floe M, Ackermann C. Antibiotic prophylaxis at urinary catheter removal prevents urinary tract infections: a prospective randomized trial. Ann Surg. 2009;249(4): 573-5.

  21. Cam K, Kayikci A, Akman Y, Erol A. Prospective assessment of the efficacy of single dose versus traditional 3-day antimicrobial prophylaxis in 12-core transrectal prostate biopsy. Int J Urol. 2008;15(11):997-1001.

  22. Tuncel A, Aslan Y, Sezgin T, Aydin O, Tekdogan U, Atan A. Does disposable needle guide minimize infectious complications after transrectal prostate needle biopsy? Urology. 2008;71(6):1024-7; discussion 1027-8.

  23. Peterson J, Kaul S, Khashab M, Fisher AC, Kahn JB. A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis. Urology. 2008;71(1):17-22.

  24. Dybowski B, JabÇonska O, Radziszewski P, Gromadzka-Ostrowska J, Borkowski A. Ciprofloxacin and furagin in acute cystitis: comparison of early immune and microbiological results. Int J Antimicrob Agents. 2008;31(2):130-4.

  25. Peterson J, Kaul S, Khashab M, Fisher A, Kahn JB. Identification and pretherapy susceptibility of pathogens in patients with complicated urinary tract infection or acute pyelonephritis enrolled in a clinical study in the United States from November 2004 through April 2006. Clin Ther. 2007;29(10):2215-21.

  26. Klausner HA, Brown P, Peterson J, et al. A trial of levofloxacin 750 mg once daily for 5 days versus ciprofloxacin 400 mg and/or 500 mg twice daily for 10 days in the treatment of acute pyelonephritis. Curr Med Res Opin. 2007;23(11):2637-45.

  27. Marcelin-Jimenez G, Angeles AP, Martinez-Rossier L, Fernandez SA. Ciprofloxacin bioavailability is enhanced by oral co-administration with phenazopyridine: a pharmacokinetic study in a Mexican population. Clin Drug Investig. 2006;26(6):323-8.

  28. Esposito S, Noviello S, Leone S, et al. A pilot study on prevention of catheter-related urinary tract infections with fluoroquinolones. J Chemother. 2006;18(5):494-501.

  29. Wagenlehner FM, Kinzig-Schippers M, Sorgel F, Weidner W, Naber KG. Concentrations in plasma, urinary excretion and bactericidal activity of levofloxacin (500 mg) versus ciprofloxacin (500 mg) in healthy volunteers receiving a single oral dose. Int J Antimicrob Agents. 2006;28(6):551-9.

  30. Mariappan P, Smith G, Moussa SA, Tolley DA. One week of ciprofloxacin before percutaneous nephrolithotomy significantly reduces upper tract infection and urosepsis: a prospective controlled study. BJU Int. 2006;98(5):1075-9.

  31. Bin C, Hui W, Renyuan Z, et al. Outcome of cephalosporin treatment of bacteremia due to CTX-M-type extended-spectrum beta-lactamáse-producing Escherichia coli. Diagn Microbiol Infect Dis. 2006;56(4):351-7.

  32. Kartal ED, Yenilmez A, Kiremitci A, Meric H, Kale M, Usluer G. Effectiveness of ciprofloxacin prophylaxis in preventing bacteriuria caused by urodynamic study: a blind, randomized study of 192 patients. Urology. 2006;67(6):1149-53.

  33. Wagenlehner FM, Kinzig-Schippers M, Tischmeyer U, et al. Pharmacokinetics of ciprofloxacin XR (1000 mg) versus levofloxacin (500 mg) in plasma and urine of male and female healthy volunteers receiving a single oral dose. Int J Antimicrob Agents. 2006;27(1):7-14.

  34. Gupta K, Hooton TM, Stamm WE. Isolation of fluoroquinolone-resistant rectal Escherichia coli after treatment of acute uncomplicated cystitis. J Antimicrob Chemother. 2005;56(1):243-6.

  35. Carmignani G, De Rose AF, Olivieri L, Salvatori E, Rosignoli MT, Dionisio P. Prulifloxacin versus ciprofloxacin in the treatment of adults with complicated urinary tract infections. Urol Int. 2005;74(4):326-31.

  36. Wazait HD, Patel HR, van der Meulen JH, et al. A pilot randomized double-blind placebo-controlled trial on the use of antibiotics on urinary catheter removal to reduce the rate of urinary tract infection: the pitfalls of ciprofloxacin. BJU Int. 2004;94(7):1048-50.

  37. Dow G, Rao P, Harding G, et al. A prospective, randomized trial of 3 or 14 days of ciprofloxacin treatment for acute urinary tract infection in patients with spinal cord injury. Clin Infect Dis. 2004;39(5):658-64.

  38. Naber KG, Allin DM, Clarysse L, et al. Gatifloxacin 400 mg as a single shot or 200 mg once daily for 3 days is as effective as ciprofloxacin 250 mg twice daily for the treatment of patients with uncomplicated urinary tract infections. Int J Antimicrob Agents. 2004;23(6):596-605.

  39. Sabbagh R, McCormack M, Piloquin F, et al. A prospective randomized trial of 1-day versus 3-day antibiotic prophylaxis for transrectal ultrasound guided prostate biopsy. Can J Urol. 2004;11(2):2216-9.

  40. Wells WG, Woods GL, Jiang Q, Gesser RM. Treatment of complicated urinary tract infection in adults: combined analysis of two randomized, double-blind, multicentre trials comparing ertapenem and ceftriaxone followed by appropriate oral therapy. J Antimicrob Chemother. 2004;53 Suppl 2:ii67-74.

  41. Valdevenito Sepúlveda JP. [Antibiotics in transurethral resection of the prostate in patients with low risk of infectious complications: randomized prospective comparative study]. Arch Esp Urol. 2004;57(1):48-57.

  42. Naber KG, Bartnicki A, Bischoff W, et al. Gatifloxacin 200 mg or 400 mg once daily is as effective as ciprofloxacin 500 mg twice daily for the treatment of patients with acute pyelonephritis or complicated urinary tract infections. Int J Antimicrob Agents. 2004;23 Suppl 1:S41-53.

  43. Vogel T, Verreault R, Gourdeau M, Morin M, Grenier-Gosselin L, Rochette L. Optimal duration of antibiotic therapy for uncomplicated urinary tract infection in older women: a double-blind randomized controlled trial. CMAJ. 2004;170(4):469-73.

  44. Talan DA, Klimberg IW, Nicolle LE, Song J, Kowalsky SF, Church DA. Once daily, extended release ciprofloxacin for complicated urinary tract infections and acute uncomplicated pyelonephritis. J Urol. 2004;171(2 Pt 1):734-9.

  45. Wagenlehner FM, Wydra S, Onda H, Kinzig-Schippers M, Sorgel F, Naber KG. Concentrations in plasma, urinary excretion, and bactericidal activity of linezolid (600 milligrams) versus those of ciprofloxacin (500 milligrams) in healthy volunteers receiving a single oral dose. Antimicrob Agents Chemother. 2003;47(12):3789-94.

  46. Ulleryd P, Sandberg T. Ciprofloxacin for 2 or 4 weeks in the treatment of febrile urinary tract infection in men: a randomized trial with a 1 year follow-up. Scand J Infect Dis. 2003;35(1):34-9.

  47. Henry DC Jr, Bettis RB, Riffer E, et al. Comparison of once-daily extended- release ciprofloxacin and conventional twice-daily ciprofloxacin for the treatment of uncomplicated urinary tract infection in women. Clin Ther. 2002;24(12):2088-104.

  48. Naber KG; European Lomefloxacin Prostatitis Study Group. Lomefloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis. Int J Antimicrob Agents. 2002;20(1):18-27.

  49. Cox CE, Marbury TC, Pittman WG, et al. A randomized, double-blind, multicenter comparison of gatifloxacin versus ciprofloxacin in the treatment of complicated urinary tract infection and pyelonephritis. Clin Ther. 2002;24(2):223-36.

  50. Auquer F, Cordinn F, Gorina E, et al. Single-dose ciprofloxacin versus 3 days of norfloxacin in uncomplicated urinary tract infections in women. Clin Microbiol Infect. 2002;8(1):50-4.

  51. Richard GA, Mathew CP, Kirstein JM, Orchard D, Yang JY. Single-dose fluoroquinolone therapy of acute uncomplicated urinary tract infection in women: results from a randomized, double-blind, multicenter trial comparing single-dose to 3-day fluoroquinolone regimens. Urology. 2002;59(3):334-9.

  52. Gomolin IH, Siami PF, Reuning-Scherer J, Haverstock DC, Heyd A; Oral Suspension Study Group. Efficacy and safety of ciprofloxacin oral suspension versus trimethoprim-sulfamethoxazole oral suspension for treatment of older women with acute urinary tract infection. J Am Geriatr Soc. 2001;49(12):1606-13.

  53. Raz R, Naber KG, Raizenberg C, et al. Ciprofloxacin 250 mg twice daily versus ofloxacin 200 mg twice daily in the treatment of complicated urinary tract infections in women. Eur J Clin Microbiol Infect Dis. 2000;19(5):327-31.

  54. Aron M, Rajeev TP, Gupta NP. Antibiotic prophylaxis for transrectal needle biopsy of the prostate: a randomized controlled study. BJU Int. 2000;85(6):682-5.

  55. Christiano AP, Hollowell CM, Kim H, et al. Double-blind randomized comparison of single-dose ciprofloxacin versus intravenous cefazolin in patients undergoing outpatient endourologic surgery. Urology. 2000;55(2):182-5.

  56. Naber KG, Theuretzbacher U, Moneva-Koucheva G, Stass H. Urinary excretion and bactericidal activity of intravenous ciprofloxacin compared with oral ciprofloxacin. Eur J Clin Microbiol Infect Dis. 1999;18(11):783-9.

  57. Price J, Ekleberry A, Grover A, et al. Evaluation of clinical practice guidelines on outcome of infection in patients in the surgical intensive care unit. Crit Care Med. 1999;27(10):2118-24.

  58. Eickhoff JH, Frimodt-Miller N, Walter S, Frimodt-Miller C. A double-blind, randomized, controlled multicentre study to compare the efficacy of ciprofloxacin with pivampicillin as oral therapy for epididimytis in men over 40 years of age. BJU Int. 1999;84(7):827-34.

  59. Henry DC, Nenad RC, Iravani A, et al. Comparison of sparfloxacin and ciprofloxacin in the treatment of community-acquired acute uncomplicated urinary tract infection in women. Sparfloxacin Multicenter Uncomplicated Urinary Tract Infection Study Group. Clin Ther. 1999;21(6): 966-81.

  60. Tsukamoto T, Matsukawa M, Sano M, et al. Biofilm in complicated urinary tract infection. Int J Antimicrob Agents. 1999;11(3-4):233-6; discussion 237-9.

  61. Iravani A, Klimberg I, Briefer C, Munera C, Kowalsky SF, Echols RM. A trial comparing low-dose, short-course ciprofloxacin and standard 7 day therapy with co-trimoxazole or nitrofurantoin in the treatment of uncomplicated urinary tract infection. J Antimicrob Chemother. 1999;43 Suppl A:67-75.

  62. McCarty JM, Richard G, Huck W, et al. A randomized trial of short-course ciprofloxacin, ofloxacin, or trimethoprim/sulfamethoxazole for the treatment of acute urinary tract infection in women. Ciprofloxacin Urinary Tract Infection Group. Am J Med. 1999;106(3):292-9.

  63. Mombelli G, Pezzoli R, Pinoja-Lutz G, Monotti R, Marone C, Franciolli M. Oral vs. intravenous ciprofloxacin in the initial empirical management of severe pyelonephritis or complicated urinary tract infections: a prospective randomized clinical trial. Arch Intern Med. 1999;159(1):53-8.

  64. Tsugawa M, Monden K, Nasu Y, Kumon H, Ohmori H. Prospective randomized comparative study of antibiotic prophylaxis in urethrocystoscopy and urethrocystography. Int J Urol. 1998;5(5):441-3.

  65. Kapoor DA, Klimberg IW, Malek GH, et al. Single-dose oral ciprofloxacin versus placebo for prophylaxis during transrectal prostate biopsy. Urology. 1998;52(4):552-8.

  66. Naber KG, Theuretzbacher U, Kinzig M, Savov O, Sorgel F. Urinary excretion and bactericidal activities of a single oral dose of 400 milligrams of fleroxacin versus a single oral dose of 800 milligrams of pefloxacin in healthy volunteers. Antimicrob Agents Chemother. 1998;42(7):1659-65.

  67. Hsieh WJ, Lin HC, Hwang SJ, et al. The effect of ciprofloxacin in the prevention of bacterial infection in patients with cirrhosis after upper gastrointestinal bleeding. Am J Gastroenterol. 1998;93(6):962-6.

  68. Viitanen J, Malminiemi K, Kallio J, Puolakka VM, Rajala P, Tammela TL. Transurethral prostatectomy in patients with preoperative bacteriuria: double-blind study with oral fleroxacin and cefalexin. Chemotherapy. 1998;44(1):69-75.

  69. Moyses Neto M, Costa RS, Reis MA, et al. Use of ciprofloxacin as a prophylactic agent in urinary tract infections in renal transplant recipients. Clin Transplant. 1997;11(5 Pt 1):446-52.

  70. Frankenschmidt A, Naber KG, Bischoff W, Kullmann K. Once-daily fleroxacin versus twice-daily ciprofloxacin in the treatment of complicated urinary tract infections. J Urol. 1997;158(4):1494-9.

  71. Rao VV, Rambhau D, Rao BR, Srinivasu P. Circadian variation in urinary excretion of ciprofloxacin after a single-dose oral administration at 1000 and 2200 hours in human subjects. Antimicrob Agents Chemother. 1997;41(8):1802-4.

  72. Lukkarinen O, Hellstrom P, Leppilahti M, Kontturi M, Tammela T. Antibiotic prophylaxis in patients with urinary retention undergoing transurethral prostatectomy. Ann Chir Gynaecol. 1997;86(3):239-42.

  73. Bierkens AF, Hendrikx AJ, Ezz el Din KE, et al. The value of antibiotic prophylaxis during extracorporeal shock wave lithotripsy in the prevention of urinary tract infections in patients with urine proven sterile prior to treatment. Eur Urol. 1997;31(1):30-5.

  74. Whitby M, Angus L, Nimmo G, Hill V. Complicated urinary infection in spinal injury patients: fleroxacin compared with ciprofloxacin. Chemotherapy. 1996;42(6):468-72.

  75. Gasser TC, Wisard M, Frei R. Oral fleroxacin prophylaxis in transurethral surgery. J Urol. 1996;156(1):146-8.

  76. Pisani E, Bartoletti R, Trinchieri A, Rizzo M. Lomefloxacin versus ciprofloxacin in the treatment of complicated urinary tract infections: a multicenter study. J Chemother. 1996;8(3):210-3.

  77. Hall JC, Christiansen KJ, England P, et al. Antibiotic prophylaxis for patients undergoing transurethral resection of the prostate. Urology. 1996;47(6):852-6.

  78. Naber KG, di Silverio F, Geddes A, Guibert J. Comparative efficacy of sparfloxacin versus ciprofloxacin in the treatment of complicated urinary tract infection. J Antimicrob Chemother. 1996;37 Suppl A:135-44.

  79. Lukkarinen O, Hellstrom P, Leppilahti M, Kontturi M, Tammela T. Prospective randomized open study between ciprofloxacin and a combination of sulfadiazine and trimethoprim in antibiotic prophylaxis in connection with transurethral prostatectomy. Scand J Urol Nephrol. 1996; 30(1):33-6.

  80. Iravani A, Tice AD, McCarty J, et al. Short-course ciprofloxacin treatment of acute uncomplicated urinary tract infection in women. The minimum effective dose. The Urinary Tract Infection Study Group [corrected]. Arch Intern Med. 1995;155(5):485-94.

  81. McCue JD, Gaziano P, Orders D. A randomised controlled trial of ofloxacin 200 mg 4 times daily or twice daily vs ciprofloxacin 500 mg twice daily in elderly nursing home patients with complicated UTI. Drugs. 1995;49 Suppl 2:368-73.

  82. Darouiche RO, Smith MS, Markowski J. Antibiotic prophylaxis for urodynamic testing in patients with spinal cord injury: a preliminary study. J Hosp Infect. 1994;28(1):57-61.

  83. Pfau A, Sacks TG. Effective postcoital quinolone prophylaxis of recurrent urinary tract infections in women. J Urol. 1994;152(1):136-8.

  84. Biering-Sorensen F, Hiiby N, Nordenbo A, Ravnborg M, Bruun B, Rahm V. Ciprofloxacin as prophylaxis for urinary tract infection: prospective, randomized, cross-over, placebo controlled study in patients with spinal cord lesion. J Urol. 1994;151(1):105-8. Erratum in: J Urol. 1994;151(4):1032.

  85. Whitby M, Brown P, Silagy C, Rana C. Comparison of fleroxacin and amoxicillin in the treatment of uncomplicated urinary tract infections in women. Am J Med. 1993;94(3A):97S-100S.

  86. Iravani A. Multicenter study of single-dose and multiple-dose fleroxacin versus ciprofloxacin in the treatment of uncomplicated urinary tract infections. Am J Med. 1993;94(3A):89S-96S.

  87. Cox CE. Comparison of intravenous fleroxacin with ceftazidime for treatment of complicated urinary tract infections. Am J Med. 1993;94(3A): 118S-125S.

  88. Naber KG, Sigl G. Fleroxacin versus ofloxacin in patients with complicated urinary tract infection: a controlled clinical study. Am J Med. 1993;94(3A):114S-117S.

  89. Pummer K. Fleroxacin versus norfloxacin in the treatment of urinary tract infections: a multicenter, double-blind, prospective, randomized, comparative study. Am J Med. 1993;94(3A):108S-113S.

  90. Childs SJ. Fleroxacin versus norfloxacin for oral treatment of serious urinary tract infections. Am J Med. 1993;94(3A):105S-107S.

  91. Pittman W, Moon JO, Hamrick LC Jr, et al. Randomized double-blind trial of high- and low-dose fleroxacin versus norfloxacin for complicated urinary tract infection. Am J Med. 1993;94(3A):101S-104S.

  92. Pfau A, Sacks TG. Single dose quinolone treatment in acute uncomplicated urinary tract infection in women. J Urol. 1993;149(3):532-4.

  93. Grubbs NC, Schultz HJ, Henry NK, Ilstrup DM, Muller SM, Wilson WR. Ciprofloxacin versus trimethoprim-sulfamethoxazole: treatment of community- acquired urinary tract infections in a prospective, controlled, double-blind comparison. Mayo Clin Proc. 1992;67(12):1163-8.

  94. Schaeffer AJ, Anderson RU. Efficacy and tolerability of norfloxacin vs. ciprofloxacin in complicated urinary tract infection. Urology. 1992;40(5):446-9.

  95. Hibberd PL, Tolkoff-Rubin NE, Doran M, et al. Trimethoprim-sulfamethoxazole compared with ciprofloxacin for the prevention of urinary tract infection in renal transplant recipients. A double-blind, randomized controlled trial. Online J Curr Clin Trials. 1992;Doc No 15:[4083 words; 46 paragraphs].

  96. Peters HJ. Sequential therapy with ofloxacin in complicated urinary tract infections: a randomized comparative study with ciprofloxacin. Infection. 1992;20(3):172-3.

  97. Van der Wall E, Verkooyen RP, Mintjes-de Groot J, et al. Prophylactic ciprofloxacin for catheter-associated urinary-tract infection. Lancet. 1992;339(8799):946-51.

  98. Cox CE. A comparison of the safety and efficacy of lomefloxacin and ciprofloxacin in the treatment of complicated or recurrent urinary tract infections. Am J Med. 1992;92(4A):82S-86S.

  99. Bailey RR, Lynn KL, Robson RA, Peddie BA, Smith A. Comparison of ciprofloxacin with netilmicin for the treatment of acute pyelonephritis. N Z Med J. 1992;105(930):102-3.

  100. Stein GE, Philip E. Comparison of three-day temafloxacin with seven-day ciprofloxacin treatment of urinary tract infections in women. J Fam Pract. 1992;34(2):180-4.

  101. Kalager T, Andersen BM, Bergan T, et al. Ciprofloxacin versus a tobramycin/ cefuroxime combination in the treatment of serious systemic infections: a prospective, randomized and controlled study of efficacy and safety. Scand J Infect Dis. 1992;24(5):637-46. Erratum in: Scand J Infect Dis. 1993;25(2):271.

  102. Iravani A. Treatment of uncomplicated urinary tract infections with temafloxacin. Am J Med. 1991;91(6A):124S-128S.

  103. Paladino JA, Sperry HE, Backes JM, et al. Clinical and economic evaluation of oral ciprofloxacin after an abbreviated course of intravenous antibiotics. Am J Med. 1991;91(5):462-70.

  104. Fang GD, Brennen C, Wagener M, et al. Use of ciprofloxacin versus use of aminoglycosides for therapy of complicated urinary tract infection: prospective, randomized clinical and pharmacokinetic study. Antimicrob Agents Chemother. 1991;35(9):1849-55.

  105. Lew MA, Kehoe K, Ritz J, et al. Prophylaxis of bacterial infections with ciprofloxacin in patients undergoing bone marrow transplantation. Transplantation. 1991;51(3):630-6.

  106. Rapp RP, Billeter M, Hatton J, Young AB, Tibbs PA, Dempsey RJ. Intravenous ciprofloxacin versus ceftazidime for treatment of nosocomial pneumonia and urinary tract infection. Clin Pharm. 1991;10(1):49-55.

  107. Karachalios GN, Georgiopoulos AN, Nasopoulou-Papadimitriou DD, Adracta DJ. Value of single-dose ciprofloxacin in the treatment of acute uncomplicated urinary tract infection in women. Drugs Exp Clin Res. 1991;17(10-11):521-4.

  108. Brouwer WK, Hoogkamp-Korstanje JA, Kuiper KM. Antibiotic prophylaxis in vaginal hysterectomy. Three doses of cefuroxime plus metronidazole versus one dose of ciprofloxacin. Pharm Weekbl Sci. 1990;12(6A):292-4; discussion 294-5.

  109. Boyko EJ, Iravani A, Silverman MH, Schelling DJ, Wright RA. Randomized, controlled trial of a 10-day course of amifloxacin versus trimethoprim- sulfamethoxazole in the treatment of acute, uncomplicated urinary tract infection. Amifloxacin Multi-Center Trial Group. Antimicrob Agents Chemother. 1990;34(4):665-7.

  110. Wolfhagen MJ, Hoepelman AI, Verhoef J. Double-blind, dose-rangefinding study of fleroxacin (RO 23-6240; AM-833) for treatment of complicated urinary tract infections. Antimicrob Agents Chemother. 1990;34(3):409-12.

  111. Van Poppel H, Willemen P, Wegge M, Kraseman P, Chysky V, Baert L. Antibiotic cover of transurethral maneuvers with ciprofloxacin and susceptibility behavior of pathogens in patients with neurogenic bladder. Urol Int. 1990;45(6):342-5.

  112. Raz R, Rottensterich E, Hefter H, Kennes Y, Potasman I. Single-dose ciprofloxacin in the treatment of uncomplicated urinary tract infection in women. Eur J Clin Microbiol Infect Dis. 1989;8(12):1040-2.

  113. Cox CE. Comparison of intravenous ciprofloxacin and intravenous cefotaxime for antimicrobial prophylaxis in transurethral surgery. Am J Med. 1989;87(5A):252S-254S.

  114. Sifuentes-Osornio J, Macas A, Amieva RI, Ramos A, Ruiz-Palacios GM. Intravenous ciprofloxacin and ceftazidime in serious infections. A prospective, controlled clinical trial with third-party blinding. Am J Med. 1989;87(5A):202S-205S.

  115. Quintero-Perez NP, Andrade-Villaneuva JF, Leon-Garnica G, Bertin-Montano M, Rodriguez-Chagollan JJ, Rodriguez-Noriega E. Efficacy and safety of intravenous ciprofloxacin in the treatment of serious infections. A comparison with ceftazidime. Am J Med. 1989;87(5A):198S-201S.

  116. Villavicencio J, Asensio de Fernandez ME, Ramirez CA. Intravenous ciprofloxacin or ceftazidime in selected infections. A prospective, randomized, controlled study. Am J Med. 1989;87(5A):191S-194S.

  117. Peacock JE Jr, Pegram PS, Weber SF, Leone PA. Prospective, randomized comparison of sequential intravenous followed by oral ciprofloxacin with intravenous ceftazidime in the treatment of serious infections. Am J Med. 1989;87(5A):185S-190S.

  118. Gallis HA, Brennan RO, Goodwin SD, Swinney V, Rumbaugh MM, Drew RH. Comparison of the safety and efficacy of intravenous ciprofloxacin and intravenous ceftazidime in the treatment of selected infections. Am J Med. 1989;87(5A):176S-180S.

  119. Levine DP, McNeil P, Lerner SA. Randomized, double-blind comparative study of intravenous ciprofloxacin versus ceftazidime in the treatment of serious infections. Am J Med. 1989;87(5A):160S-163S.

  120. Fass RJ, Plouffe JF, Russell JA. Intravenous/oral ciprofloxacin versus ceftazidime in the treatment of serious infections. Am J Med. 1989;87(5A):164S-168S.

  121. Abbas AM, Chandra V, Dongaonkar PP, et al. Ciprofloxacin versus amoxycillin/clavulanic acid in the treatment of urinary tract infections in general practice. J Antimicrob Chemother. 1989;24(2):235-9.

  122. Shearman CP, Silverman SH, Johnson M, et al. Single dose, oral antibiotic cover for transurethral prostatectomy. Br J Urol. 1988;62(5): 434-8.

  123. Kosmidis J, Gargalianos P, Adamis G, Petropoulou D, Makris D. Fleroxacin in single dose oral therapy of uncomplicated lower urinary tract infection. J Antimicrob Chemother. 1988;22 Suppl D:219-21.

  124. Polubiec A, Weuta H, Stepka K, Ktos K, Strazynska R, Jorasz J. Bacterial infections of the lower urinary tract treated with ciprofloxacin or cefalexin-- a comparative study. Infection. 1988;16 Suppl 1:S62-4.

  125. Goldstein EJ, Kahn RM, Alpert ML, Ginsberg BP, Greenway FL, Citron DM. Ciprofloxacin versus cinoxacin in therapy of urinary tract infections. A randomized, double-blind trial. Am J Med. 1987;82(4A):284-7.

  126. Garlando F, Rietiker S, Tiuber MG, Flepp M, Meier B, Lothy R. Single- dose ciprofloxacin at 100 versus 250 mg for treatment of uncomplicated urinary tract infections in women. Antimicrob Agents Chemother. 1987;31(2):354-6.

  127. Henry NK, Schultz HJ, Grubbs NC, Muller SM, Ilstrup DM, Wilson WR. Comparison of ciprofloxacin and co-trimoxazole in the treatment of uncomplicated urinary tract infection in women. J Antimicrob Chemother. 1986;18 Suppl D:103-6.

  128. Gonzalez MA, Moranchel AH, Duran S, et al. Multiple-dose pharmacokinetics of ciprofloxacin administered intravenously to normal volunteers. Antimicrob Agents Chemother. 1985;28(2):235-9.

  129. Giamarellou H, Efstratiou A, Tsagarakis J, Petrikkos G, Daikos GK. Experience with ciprofloxacin in vitro and in vivo. Arzneimittelforschung. 1984;34(12):1775-8.

  130. Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. BMJ. 1994;309(6964):1286-91.

  131. Lefebvre C, McDonald S. Development of a sensitive search strategy for reports of randomized controlled trials in EMBASE. Fourth International Cochrane Colloquium; 1996 Oct 20-24; Adelaide (Australia).



>Revistas >Gaceta Médica de México >Año2015, No. 2
 

· Indice de Publicaciones 
· ligas de Interes 






       
Derechos Resevados 2019